TGRX-326 Pharmacokinetic Food Effect Bioavailability Study
Status:
COMPLETED
Trial end date:
2024-01-19
Target enrollment:
Participant gender:
Summary
A study evaluating the effects of food intake on the pharmacokinetic (PK) profiles of TGRX-326 and the effect of different drug specifications on human bioavailability for TGRX-326, a drug indicated for non-small cell lung cancer treatment
Phase:
PHASE1
Details
Lead Sponsor:
Shenzhen TargetRx, Inc.
Collaborator:
The First Affiliated Hospital of Bengbu Medical University